Effectiveness of different treatments in obesity hypoventilation syndrome.


Journal

Pulmonology
ISSN: 2531-0437
Titre abrégé: Pulmonology
Pays: Spain
ID NLM: 101723786

Informations de publication

Date de publication:
Historique:
received: 14 05 2020
accepted: 15 05 2020
pubmed: 20 6 2020
medline: 28 7 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

Obesity hypoventilation syndrome (OHS) is an undesirable consequence of obesity, defined as daytime hypoventilation, sleep disorder breathing and obesity; during the past few years the prevalence of extreme obesity has markedly increased worldwide consequently increasing the prevalence of OHS. Patients with OHS have a lower quality of life and a higher risk of unfavourable cardiometabolic consequences. Early diagnosis and effective treatment can lead to significant improvement in patient outcomes; therefore, such data has noticeably raised interest in the management and treatment of this sleep disorder. This paper will discuss the findings on the main current treatment modalities OHS will be discussed.

Identifiants

pubmed: 32553827
pii: S2531-0437(20)30128-8
doi: 10.1016/j.pulmoe.2020.05.012
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-377

Informations de copyright

Copyright © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

V R Ramírez Molina (VR)

Pulmonary and Sleep Medicine, Regional General Hospital N.2 of the Mexican Social Security Institute (IMSS), Querétaro, Mexico.

J F Masa Jiménez (JF)

Division of Pulmonary Medicine, San Pedro de Alcántara Hospital, Cáceres, Spain; CIBER of Respiratory Diseases (CIBERES), Madrid, Spain. Electronic address: fmasa@separ.es.

F J Gómez de Terreros Caro (FJ)

Division of Pulmonary Medicine, San Pedro de Alcántara Hospital, Cáceres, Spain.

J Corral Peñafiel (J)

Division of Pulmonary Medicine, San Pedro de Alcántara Hospital, Cáceres, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH